Signal transducer and activator of transcription 1 (STAT1) is activated in the inflammatory response to interferons. The MUC1 oncoprotein is overexpressed in human breast cancers. Analysis of genes differentially expressed in MUC1-transformed cells has identified a network linking MUC1 and STAT1 that is associated with cellular growth and inflammation. The results further show that the MUC1-C subunit associates with STAT1 in cells and the MUC1-C cytoplasmic domain binds directly to the STAT1 DNA-binding domain. The interaction between MUC1-C and STAT1 is inducible by IFNc in non-malignant epithelial cells and constitutive in breast cancer cells. Moreover, the MUC1-STAT1 interaction contributes to the activation of STAT1 target genes, including MUC1 itself. Analysis of two independent databases showed that MUC1 and STAT1 are coexpressed in about 15% of primary human breast tumors. Coexpression of MUC1 and the STAT1 pathway was found to be significantly associated with decreased recurrence-free and overall survival. These findings indicate that (i) MUC1 and STAT1 function in an autoinductive loop, and (ii) activation of both MUC1 and the STAT1 pathway in breast tumors confers a poor prognosis for patients.
Introduction
Signal transducer and activator of transcription 1 (STAT1) is activated in the inflammatory response to type I and II interferons. Both types of interferons induce tyrosine phosphorylation of STAT1 by the IFN receptor-associated Janus-activated kinase (JAK) 1, JAK2 and Tyk2 (Schindler et al., 2007) . Type I IFN (IFNa, IFNb) induces the assembly of STAT1 in the ISGF3 complex with STAT2 and IRF9. With type II IFNg stimulation, STAT1 forms homodimers, is imported into the nucleus and activates transcription of target genes with IFNg-activated sites (GAS; TTTCCNGGAAA) (Levy and Darnell, 2002; Schindler et al., 2007) . IFNg/STAT1 target genes encode proteins that in large part promote inflammation and inhibition of growth (Der et al., 1998; Schindler et al., 2007) . Receptor tyrosine kinases, such as the epidermal growth factor receptor (EGFR) and the platelet-derived growth factor receptor, have also been shown to directly or indirectly mediate tyrosine phosphorylation and thereby activation of STAT1 (Darnell et al., 1994; Levy and Darnell, 2002) . In contrast to these inducible responses, STAT1 is constitutively activated in human breast and other types of tumors (Yu and Jove, 2004) . The constitutive activation of STAT1 in malignant cells has been associated with the induction of prosurvival genes and suppression of the death response to ionizing radiation and other forms of stress (Khodarev et al., 2004 (Khodarev et al., , 2007 . Based on these observations, an experimentally derived IFN-related DNA damage resistance gene signature that includes STAT1 and STAT1 target genes was identified in association with resistance to ionizing radiation and chemotherapy (Weichselbaum et al., 2008) . Analysis of a breast cancer microarray database further showed that the IFN-related DNA damage resistance gene signature predicts for poor outcomes for breast cancer patients receiving adjuvant chemotherapy and for local-regional control after radiation (Weichselbaum et al., 2008) . These findings have supported a role for STAT1 in regulating the response of human breast cancer cells to genotoxic stress.
The mucin 1 (MUC1) oncoprotein is aberrantly overexpressed in human breast tumors (Kufe et al., 1984) . MUC1 consists of two subunits that after cleavage of a single polypeptide, form a complex of an N-terminal mucin component (MUC1-N) and a transmembrane C-terminal (MUC1-C) subunit (Ligtenberg et al., 1992; Macao et al., 2006) . MUC1-C functions as a cell membrane receptor that interacts with the ligand galectin-3 and associates with EGFR (Li et al., 2001b; Ramasamy et al., 2007) . The MUC1-C cytoplasmic domain (MUC1-CD) is a substrate for EGFR, c-Src, c-Abl and certain serine-threonine kinases (Li et al., 1998 (Li et al., , 2001a Ren et al., 2002; Raina et al., 2006) . MUC1-C accumulates in the cytosol of breast cancer cells and is targeted to the nucleus, in which it interacts with estrogen receptor a (ERa) and coactivates ERa target genes (Wei et al., 2006; Leng et al., 2007) . MUC1-C also interacts with the p53 tumor suppressor and b-catenin, and contributes to the regulation of p53-and Wnt/b-catenin-mediated transcription (Huang et al., 2003 (Huang et al., , 2005 Wei et al., 2005) . Other studies have shown that MUC1-C is targeted to mitochondria and blocks stress-induced apoptosis (Yin and Kufe, 2003; Ren et al., 2004 Ren et al., , 2006 Yin et al., 2007) . In concert with the involvement of MUC1-C in diverse pathways that have been linked to transformation, overexpression of MUC1-C and specifically the MUC1-C cytoplasmic domain in 3Y1 rat fibroblasts induces (i) an increase in growth rate, (ii) colony formation in soft agar and (iii) tumorigenicity in nude mice Huang et al., 2005) . MUC1-CD also induces transcriptional programs that are highly predictive of a clinical outcome for patients with breast cancer Pitroda et al., 2009 ). These findings have indicated that MUC1-mediated transcriptional regulation contributes at least in part to the malignant phenotype in experimental models and in breast tumors.
These studies show that MUC1-induced transformation is linked to activation of the STAT1-induced gene network. The basis for this finding is supported by the demonstration that MUC1-C interacts directly with STAT1 and, in an auto-inductive loop, MUC1 contributes to STAT1-mediated activation of the MUC1 gene itself and of STAT1 target genes. We also show that coexpression of MUC1 and STAT1 is of importance to outcome for patients with breast cancer.
Results
Linkage of MUC1 and STAT1 in a functional gene network Stable transfection of 3Y1 cells with MUC1-CD is associated with transformation and the activation of genes that functionally contribute to tumorigenesis (Huang et al., 2005; Khodarev et al., 2009) . In this work, analysis of gene expression in 3Y1/MUC1-CD, as compared with 3Y1/vector, cells growing in vitro has identified activation of IFNg-inducible/STAT1-dependent genes, including STAT1 itself (Figure 1a , Supplementary Table 1 ). Expression of the IFNg/STAT1 genes was 2.15-fold higher in 3Y1/MUC1-CD, as compared with 3Y1/vector, cells (P ¼ 2.6eÀ3; two-tailed t-test across all genes). Moreover, growth of the 3Y1/ MUC1-CD cells as tumors in nude mice, as compared with that in vitro, was associated with further activation (2.96-fold) of the IFNg/STAT1 pathway genes (Figure 1b, Supplementary Table 2 ; P ¼ 1.2e-4).
Although these results indicate that MUC1-CD expression is associated with activation of STAT1 signaling, we used Ingenuity Pathway Analysis (IPA) to assess linkage of the MUC1-CD and STAT1 path-ways. Analysis of genes differentially expressed in 3Y1/MUC1-CD cells growing in vivo identified a gene network containing MUC1 and STAT1 that is associated with cellular growth and inflammation ( Figure 2a ). As measured by Fisher's exact test, the linkage of MUC1 and STAT1 in this network was most significant of all that were analyzed at P ¼ 10eÀ45. This network complements the data in Figure 1 by showing that the linkage between MUC1 and STAT1 is associated with activation of IFNg/STAT1 genes as well as a complex web of gene interactions related to growth and inflammation. For example, there appeared to be an association of both STAT1 and MUC1 with TGFb in the gene network ( Figure 2a ); however, we were unable to identify significant changes in TGFb expression. Nonetheless, analysis of other networks linking MUC1 and STAT1 identified additional upregulated genes, including IFIT1 associated with cancer, the cell cycle and cell death (P ¼ 10eÀ25), IFN-induced transmembrane protein 1 (IFITM1) associated with lipid metabolism, small molecule biochemistry and molecular transport (P ¼ 10eÀ26), IFI44L associated with the cell cycle, cancer and cell death (P ¼ 10eÀ24) and ISG15 associated with cancer, gastrointestinal disease and cell growth and proliferation (P ¼ 10eÀ22). To further assess the effects of MUC1-CD on MUC1 and STAT1 in poor prognosis breast cancer N Khodarev et al STAT1-mediated transcription, we stimulated the 3Y1/ vector and 3Y1/MUC1-CD cells with IFNg ( Figure 2b ). As determined by quantitative RT-PCR, expression of marker genes of the IFNg/STAT1 pathway, including IFIT1, IFITM1 and STAT1 itself, was upregulated by MUC1-CD, confirming that MUC1-CD contributes to STAT1-mediated transcription (Figure 2b) . These results indicate that MUC1-CD-induced transformation and STAT1 pathway activation leads to the upregulation of genes involved in diverse biological processes that contribute to tumorigenesis.
MUC1-CD interacts directly with STAT1
To determine whether MUC1-CD associates with STAT1, lysates from 3Y1/MUC1-CD cells were immunoprecipitated with an antibody against the MUC1 cytoplasmic domain or, as a control, with a non-immune IgG. Immunoblot analysis of the precipitates with anti-STAT1 showed that MUC1-CD forms complexes with STAT1 ( Figure 3a ). Incubation of GST and GST-MUC1-CD with purified recombinant STAT1 further showed that MUC1-CD binds directly to STAT1 (Figure 3b ). To further define the region of MUC1 and STAT1 in poor prognosis breast cancer N Khodarev et al MUC1-CD responsible for the interaction, we incubated MUC1-CD deletion mutants with STAT1. Binding to STAT1 was predominant with MUC1-CD(46-72), indicating that the C-terminal region of MUC1-CD confers the interaction (Figure 3b , left). In concert with these results, mutation of the serine-rich motif (SRM: SAGNGGSSLS to AAGNGGAAAA) in the MUC1-CD C-terminal region abrogated the interaction with STAT1 (Figure 3b , right). The structure of STAT1 includes a dimerization domain at the N terminus, a central DNA-binding domain (DBD) and C-terminal transactivation domain (Levy and Darnell, 2002) ( Figure 3c ). Incubation of purified MUC1-CD with STAT1 deletion mutants showed binding to the DBD and not the dimerization or transactivation domains ( Figure 3c ). These findings indicate that MUC1-CD associates with STAT1 in 3Y1/MUC1-CD cells through a direct interaction between these proteins.
Interaction between MUC1-C and STAT1 is an IFNginducible response in MCF-10A breast epithelial cells
The non-malignant MCF-10A breast epithelial cells express endogenous MUC1 (Ahmad et al., 2007) . As shown for human mammary epithelial cells (Lagow and Carson, 2002) , stimulation of MCF-10A cells with IFNg was associated with marked upregulation of MUC1-C protein (Figure 4a , left). RT-PCR analysis of the IFNgtreated MCF-10A cells further showed increases in MUC1 mRNA levels, consistent with transcriptional activation (Figure 4a , right). Notably, there was little if any association between MUC1-C and STAT1 in unstimulated MCF-10A cells; however, IFNg stimulation was associated with the detection of MUC1-C-STAT1 complexes (Figure 4b ). To determine whether STAT1 is responsible for IFNg-induced upregulation of MUC1 expression, the MCF-10A cells were transfected with control or STAT1 siRNA pools. As expected, induction of STAT1 expression by IFNg was attenuated by the STAT1 siRNA ( Figure 4c ). Moreover, silencing STAT1 was associated with attenuation of IFNginduced expression of MUC1-C ( Figure 4c ). Based on the findings that MUC1-CD promotes IFNg-induced expression of STAT1 in 3Y1 cells, MCF-10A cells were treated with the MUC1-C inhibitor, GO-201 ) and then stimulated with IFNg. Inhibiting MUC1-C function attenuated IFNg-induced induction of MUC1-C expression, supporting a role for MUC1 in upregulating MUC1 gene activation ( Figure 4d ). In addition and significantly, GO-201 treatment was associated with inhibition of IFNg-induced expression of STAT1 ( Figure 4d ). Moreover, GO-201 inhibited induction of the IFITM1, which is encoded by an IFNg/ STAT1 pathway target gene (Deblandre et al., 1995) . By contrast, an inactive form of GO-201, designated CP-1 , had little effect (Figure 4d ). To confirm these findings, MCF-10A cells were transfected with control or MUC1 siRNA pools as described ) and then stimulated with IFNg. Real-time RT-PCR analysis showed that IFNg-induced activation of IFITM1 gene expression is blocked by silencing MUC1 (Figure 4e ). These findings indicated 
MUC1-C-STAT1 complexes occupy the MUC1 gene promoter
To determine whether MUC1-C is detectable in the STAT1 transcription complex, ChIP analysis was performed on a consensus STAT-binding motif from À503 to À495; (TTCCGGGAA) in the MUC1 promoter that has been documented as a STAT-binding site (Gaemers et al., 2001) . Precipitation of chromatin from MCF-10A cells with anti-STAT1 showed a low level of STAT1 on the STAT-binding site (SBS) (Figure 5a ). By contrast, STAT1 occupancy was undetectable on a control region (CR; þ 4524 to þ 4745) ( Figure 5a ). Significantly, treatment with IFNg was associated with an increase in STAT1 occupancy (Figure 5a ). ChIP analysis also showed that MUC1-C occupies the SBS in response to IFNg stimulation (Figure 5b ). Overexpres-sion of endogenous MUC1 in ZR-75-1 breast cancer cells is associated with constitutive binding of MUC1-C and STAT1 (Figure 5c ). ChIP analysis of the MUC1 promoter in ZR-75-1/vector cells further showed that STAT1 constitutively occupies the SBS and not the control region (Figure 5d ). Moreover, re-ChIP studies confirmed that MUC1-C coprecipitates with STAT1 on the STAT-binding site (Figure 5d ). Notably, stable silencing of MUC1 in ZR-75-1/MUC1 siRNA cells (Ahmad et al., 2007) resulted in decreased STAT1 occupancy of the SBS and, as expected, loss of MUC1-C in the re-ChIP (Figure 5d ). In contrast to these results and as a control, there was no detectable STAT5 occupancy of the MUC1 promoter SBS in MCF-10A and ZR-75-1 cells (Supplementary Figure 1) . These findings show that MUC1-C associates with the STAT1 transcription complex and that MUC1-C contributes to STAT1 occupancy of the MUC1 promoter.
MUC1 associates with STAT1 pathway activation in poor prognosis human breast tumors An expressional database representing 327 cases of breast cancer (80.1% ER þ ) (Loi et al., 2007) was analyzed to assess the clinical significance of MUC1 and STAT1 coexpression. We found that MUC1 and STAT1 were coexpressed in 13.8% (n ¼ 45) of the breast tumors (Figure 6a ). STAT1 only was expressed in 17.7% of the tumors and MUC1 only expression was detected in 23.9%. Hierarchical clustering of the database based on expression of the STAT1 pathway (24 genes) (Khodarev et al., 2004; Weichselbaum et al., 2008) showed differences in expression throughout the 327 breast tumors (Figure 6b ). Importantly, STAT1 pathway expression was significantly (Fisher's exact test; P ¼ 0.0003) associated with coexpression of MUC1 (Figure 6b ), indicating that MUC1 expression is associated with activation of the STAT1 pathway. Using Kaplan-Meier survival analysis, we found that patients with tumors coexpressing MUC1 (MUC1 þ ) and the STAT1 pathway (STAT1P þ ) (n ¼ 49) had significantly reduced (log-rank P ¼ 0.036) recurrencefree survival compared to patients with tumors without coexpression (n ¼ 257) (Figure 6c ). No differences in recurrence-free survival were found between MUC1À/ STAT1PÀ, MUC1 þ /STAT1PÀ or MUC1À/ STAT1P þ patients (log-rank P>0.05). Overall survival data are not available for this database. Also, coexpression of MUC1 and STAT1 was not significantly associated with ER status (Fisher's exact test; P ¼ 0.66). The breast cancer database (Loi et al., 2007) used for these studies does not provide information about ErbB2 expression, thus it was not possible to assess coexpression of MUC1 and STAT1 in triplenegative breast cancers. We also found that MUC1 þ / STAT1P þ status is not associated with the presence of positive lymph nodes, high tumor grade (grade 2 and 3) or tumor size (Fisher's exact test; 0.23pPp0.66). Given that coexpression is not linked to these tumor parameters, we hypothesized that MUC1 þ /STAT1P þ status could enhance the identification of clinically (c) Lysates from ZR-75-1 cells were immunoprecipitated with anti-MUC1-C or a control IgG. The precipitates were immunoblotted with the indicated antibodies. (d) Soluble chromatin from ZR-75-1/ vector and ZR-75-1/MUC1siRNA cells was precipitated with anti-STAT1 and analyzed for MUC1 promoter SBS and CR sequences. In re-ChIP analysis, the anti-STAT1 precipitates were released, reimmunoprecipitated with anti-MUC1-C and then analyzed for MUC1 promoter sequences.
MUC1 and STAT1 in poor prognosis breast cancer N Khodarev et al aggressive tumors. In this regard, for patients with highgrade tumors (grades 2 and 3), MUC1 þ /STAT1P þ status (n ¼ 32) significantly predicted (log-rank P ¼ 0.030) reduced recurrence-free survival compared with non-coexpressors (n ¼ 169) (Figure 6d ). There were again no differences in recurrence-free survival among patients with MUC1À/STAT1PÀ, MUC1 þ /STAT1PÀ or MUC1À/STAT1P þ (log-rank P>0.05) high-grade tumors. Analysis of an independent database of 155 breast cancers (94.8% ER þ ) (Chanrion et al., 2008) showed coexpression of MUC1 and STAT1 in 16.1% (Figure 7a ). The results also confirmed that expression of the STAT1 pathway across the 155 tumors was significantly associated with MUC1 expression (Fisher's exact test Po0.0001; Figure 7b ). Notably, patients with MUC1 þ /STAT1P þ tumors had a 7.38-foldincreased risk for recurrence (95% confidence interval (CI): 1.66-23.7; P ¼ 0.012) and a 4.10-fold-increased risk for death (95% CI: 1.55-9.11; P ¼ 0.0070) compared with non-coexpressors ( Figure 7c ). Furthermore, as found for the first database, grade 2 and 3 tumors with MUC1 þ /STAT1P þ status had significantly increased risks for recurrence (Hazard Ratio (HR) ¼ 6.21; 95% CI: 1.40-19.94; P ¼ 0.020) and death (HR ¼ 3.40; 95% CI: 1.28-7.57; P ¼ 0.017) compared with non-coexpressors ( Supplementary Table 3 ). Taken together, these data show that MUC1 and STAT1 are coexpressed in breast tumors and that activation of the STAT1 pathway in association with MUC1 expression predicts reduced recurrence-free and overall survival in patients.
Discussion
MUC1 and STAT1 form a gene network STAT1 is constitutively activated in breast and other types of cancer, although the functional significance of this response has been largely unknown (Yu and Jove, 2004) . Indeed, STAT1 target genes in the non-malignant setting have been associated with inflammation, antiproliferative effects and a tumor suppressor function (Schindler et al., 2007) . However, paradoxically, recent studies have shown that constitutive activation of the STAT1 pathway in malignant cells in vitro and in human breast tumors confers resistance to genotoxic anti-cancer agents (Khodarev et al., 2004 (Khodarev et al., , 2007 Weichselbaum et al., 2008) . Notably, the overexpression Figure 6 Coexpression of MUC1 and the STAT1 pathway is associated with reduced recurrence-free survival. (a) An expressional database derived from 327 breast tumors was analyzed for expression of MUC1 (MUC1 þ ) and STAT1 (STAT1 þ ). Coexpression was detectable in 45 tumors (13.8%). Hierarchical clustering for expression of the STAT1 pathway (24 genes) was performed for the entire database. Relative expression values are in log 2 scale. Activation of the STAT1 pathway (STAT1P þ ) was significantly associated with MUC1 expression (49 tumors; Fisher's exact test, P ¼ 0.0003). (b) Kaplan-Meier curves for recurrence-free survival were determined for patients with MUC1 þ /STAT1P þ tumors (n ¼ 49; red curve) compared with those patients without coexpression (n ¼ 257; blue curve). (c) Kaplan-Meier curves were determined for recurrence-free survival of patients with grade 2/3 tumors that are MUC1 þ /STAT1P þ (n ¼ 32; red curve) compared with those patients with grade 2/3 tumors without coexpression (n ¼ 169; blue curve). A full colour version of this figure is available at the Oncogene journal online. of MUC1 in breast cancer cells confers resistance to DNA-damaging chemotherapeutic agents (Ren et al., 2004) , suggesting that MUC1 and STAT1 may have similar roles. In this work, analysis of 3Y1 cells transformed with MUC1-CD showed upregulation of the STAT1 gene and STAT1 target genes in vitro and in an animal xenograft model. Moreover, IFNg-induced activation of the STAT1 pathway was increased by MUC1-CD expression, supporting a potential role for MUC1-CD in promoting STAT1-mediated transcription. By using Ingenuity Pathway Analysis to functionally classify genes differentially expressed in MUC1-CD-transformed cells, we confirmed a highly significant interaction between the MUC1 and STAT1 pathways. This network included a set of genes encoding proteins involved in the inflammatory response, consistent with that found for the IFNg/STAT1 pathway. In contrast to induction of anti-proliferative genes by the IFNg/STAT1 pathway in non-malignant cells, the MUC1 and STAT1 network associated with transformation also included genes that confer a proliferative response. These findings raised the possibility that the MUC1 and STAT1 proteins interact in the regulation of STAT1-mediated gene transcription.
MUC1-C interacts directly with STAT1 in an auto-inductive loop
The MUC1-C transmembrane subunit is targeted to the nucleus of breast cancer cells where it interacts with ERa on estrogen-responsive promoters and contributes to the regulation of ERa-mediated transcription (Wei et al., 2006) . MUC1-C has also been directly implicated in the regulation of other transcription factors, including p53 (Wei et al., 2005 (Wei et al., , 2007 . The present studies show that MUC1-C associates with STAT1 as an IFNg-inducible response in MCF-10A breast epithelial cells and constitutively in ZR-75-1 breast cancer cells. This interaction is mediated, at least in large part, by direct binding of the MUC1-CD C-terminal region and the STAT1 DBD. Significantly, mutation of the MUC1-CD serine-rich motif in the C-terminal region abrogated the interaction with STAT1 and, as reported, also blocks MUC1-CD-induced anchorage-independent growth and tumorigenicity of 3Y1 cells (Huang et al., 2005) . In addition, little is known about proteins that interact with the STAT1 DBD (Shuai, 2000) . This region contains a functional nuclear export signal that interacts with CRM1 and confers leptomycin B-sensitive export of nuclear STAT1 that has undergone tyrosine dephosphorylation (McBride et al., 2000; Meyer et al., 2003) . The STAT1 DBD also contains two lysines that, when acetylated by the histone acetyltransferase CBP, promotes tyrosine dephosphorylation of STAT1 by TCP45 (Kra¨mer et al., 2006 (Kra¨mer et al., , 2009 . Thus, binding of MUC1-C to the STAT1 DBD could affect interactions with CBP and/or TCP45 and prolong occupancy of STAT1 on its cognate responsive elements. In this regard, ChIP analysis showed that both MUC1-C and STAT1 occupy the STAT-binding site in the MUC1 promoter. Moreover, silencing MUC1 was associated with decreased STAT1 occupancy of that site, indicating that MUC1-C may delay STAT1 latency. The demonstration that (i) MUC1-C promotes STAT1-mediated transcription of the MUC1 gene, and (ii) downregulation of MUC1-C levels blocks induction of STAT1 and IFITM1 expression provided further support for the induction of an auto-inductive loop in which MUC1-C and STAT1 work cooperatively to activate expression of STAT1dependent genes, including the MUC1 gene itself (Figure 7c ). The results also show that inhibition of MUC1-C function with GO-201 blocks IFNg-induced activation of the STAT1 pathway. Notably, GO-201 induces complete regressions of human breast tumor Coexpression was detectable in 25 tumors (16.1%). Hierarchical clustering for expression of the STAT1 pathway (24 genes) was performed for all tumors. Relative expression values are in log 2 scale. Activation of the STAT1 pathway (STAT1P þ ) was significantly associated with MUC1 expression (Po0.0001). Genes having significantly increased expression in MUC1 þ tumors are shown. (b) Hazard ratios for recurrence-free and overall survival were determined for patients with MUC1 þ /STAT1P þ tumors (n ¼ 8) compared with those patients without coexpression (n ¼ 147) (left panel). Hazard ratios for recurrence-free and overall survival were determined for patients with grade 2/3 tumors that are MUC1 þ /STAT1P þ (n ¼ 8) compared with those patients with grade 2/3 tumors without coexpression (n ¼ 126) (right panel). (c) Proposed schema for an MUC1-STAT1 auto-inductive loop. A full colour version of this figure is available at the Oncogene journal online.
MUC1 and STAT1 in poor prognosis breast cancer N Khodarev et al xenografts in preclinical models and thus could confer these responses, at least in part, by downregulation of the STAT1 pathway ). Based on these findings, STAT1 inhibitors could be effective in downregulating MUC1-C expression and thereby tumorigenicity. Whether the constitutive activation of a MUC1-STAT1 loop in breast cancer cells contributes to a function of STAT1 in promoting a more aggressive phenotype, as recently reported (Weichselbaum et al., 2008) , was not known, and consequently was addressed using microarray databases from breast cancer patients treated with adjuvant therapy.
Coexpression of MUC1 and the STAT1 pathway in human breast tumors confers a poor prognosis Stimulation of non-malignant MCF-10A breast epithelial cells with IFNg was associated with STAT1dependent induction of MUC1 expression, formation of MUC1-C-STAT1 complexes and occupancy of these complexes on the MUC1 promoter. In contrast to this IFNg inducible interaction, the association between MUC1-C and STAT1 and their occupancy of the MUC1 promoter is constitutive in ZR-75-1 breast cancer cells, suggesting that activation of the MUC1 and STAT1 pathways may be present in primary breast tumors. Indeed, analysis of two breast cancer databases showed coexpression of MUC1 and STAT1 in about 15% of tumors. Importantly, as determined by hierarchical clustering, MUC1 expression was significantly (Pp0.0003) associated with activation of the STAT1 pathway. The significance of this association is supported by the finding that patients with tumors coexpressing MUC1 and the STAT1 pathway had significantly increased risks for recurrence and death. Coexpression of MUC1 and the STAT1 pathway was not related to ER status, high tumor grades (2 and 3) or tumor size. However, risk of recurrence and death was significantly increased for patients with grade 2 and 3 tumors that coexpressed MUC1 and the STAT1 pathway, supporting involvement of the interaction in clinically aggressive breast cancers. These findings support activation of the MUC1 and STAT1 pathways in conferring reduced recurrence-free and overall survival in breast cancer patients and suggest that MUC1-C and/or STAT1 inhibitors could be effective in treating this population. In this context, the epithelial cell barrier is exposed to diverse forms of stress, including inflammatory signals, and the MUC1-C receptor functions in transducing signals that protect epithelial cells from stress-induced death (Ren et al., 2004; Wei et al., 2005; Yin et al., 2007) . Activation of MUC1 expression by a STAT1-dependent auto-inductive loop would appear to be an inducible response in non-malignant cells that is constitutively activated in certain breast cancers. Thus, what may represent a physiological mechanism to protect the mammary epithelium from an IFNg/STAT1-induced response could have been exploited by breast cancers to survive under adverse inflammatory conditions through a previously unrecognized STAT1 tumorigenic function.
Materials and methods

Cell culture
Rat 3Y1 fibroblasts transfected to stably express an empty vector (3Y1/vector; two clones A and B) or one expressing the MUC1-C cytoplasmic domain (3Y1/MUC1-CD; two clones A and B) were grown in vitro as described (Huang et al., 2005) . The 3Y1/vector and 3Y1/MUC1-CD cells were treated with 20 ng/ml rat IFNg (R&D Systems, Minneapolis, MN, USA). Human ZR-75-1, ZR-75-1/vector and ZR-75-1/MUC1siRNA breast cancer cells (Ren et al., 2004) were grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, 100 mg/ml streptomycin, 100 units/ml penicillin and 2 mM L-glutamine. Human MCF-10A breast epithelial cells were grown in mammary epithelial cell growth medium (MEGM; Lonza, Walkersville, MD, USA) and treated with 20 ng/ml human IFNg (R&D Systems). Transfection of MCF-10A cells with siRNA pools (Dharmacon, Lafayette, CO, USA) was performed in the presence of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were treated with the MUC1-C inhibitor GO-201 or the control CP-1 as described ).
Analysis of DNA microarrays
RNA purification and hybridization with GeneChip Rat Genome 230 2.0. Arrays (Affymetrix, Santa Clara, CA, USA) was performed as described (Kimchi et al., 2005) . The selection and analysis of genes differentially expressed in 3Y1/ vector and 3Y1/MUC1-CD cells in vitro was based on previously detailed approaches (Khodarev et al., 2003 (Khodarev et al., , 2004 . 3Y1/MUC1-CD cells were grown subcutaneously in female athymic mice and the tumors were harvested for RNA extraction for analysis of gene expression as described Pitroda et al., 2009) . Briefly, each array was hybridized with a pooled sample normalized to total RNA and consisting of RNA obtained from three independent xenografts or cell lines. Data were normalized using 'global median normalization' across the entire data set (Kimchi et al., 2005) and filtrated using multi-step filtration (Khodarev et al., 2004) . Subsequent analysis was based on pairwise comparisons (3Y1/vector in vitro vs 3Y1/MUC1-CD in vitro and 3Y1/ MUC1-CD in vitro vs 3Y1/MUC1-CD in vivo) of duplicated arrays using Significance Analysis of Microarrays (SAM) (Tusher et al., 2001) . Differentially expressed probe set IDs were selected using a 2.0-fold induction cutoff level. Selected probe set IDs were annotated and functionally designated using Ingenuity Pathways Analysis (Ingenuity Systems Inc., Redwood City, CA, USA). Fisher's exact test was used to estimate the significance of functional networks within a given experimental data set. This method estimates the likelihood that Network Eligible Molecules from an experimental data set are linked in a specific network by random chance. A P-valuep0.05 is considered significant and indicates a nonrandom enrichment of an experimental data set by members of a specific functional network.
Immunoprecipitation and immunoblotting
Lysates from sub-confluent cells were prepared as described (Ren et al., 2004) . Soluble proteins were precipitated with anti-MUC1-C (Ab5; Lab Vision, Fremont, CA, USA) or anti-STAT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The precipitates and cell lysates were immunoblotted with anti-STAT1, anti-MUC1-C, anti-b-actin (Sigma, St Louis, MO, USA) and anti-IFITM1 (Proteintech Group, Chicago, IL, USA). Immune complexes were detected with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (GE Healthcare Biosciences, Piscataway, NJ, USA).
In vitro binding assays GST, GST-MUC1-CD, GST-MUC1-CD(1-45), GST-MUC1-CD(46-72) and GST-MUC1-CD(mSRM) were prepared as described (Huang et al., 2005; Ahmad et al., 2007) and incubated with purified recombinant STAT1. GST-STAT1 and certain GST-STAT1 deletion mutants were incubated with purified MUC1-CD that had been cleaved with thrombin to remove the GST moiety. Adsorbates to glutathioneconjugated beads were analyzed by immunoblotting.
Real-time RT-PCR Total RNA was isolated from cells using the RNeasy isolation kit (Qiagen, Valencia, CA, USA). Equal amounts of RNA were analyzed with the Superscript III platinum SYBER green one step qRT-PCR kit (Invitrogen, Carlsbad, CA, USA) on an ABI 7900HT RT-PCR machine (Applied Biosystems, Foster City, CA, USA). The human HPRT gene was used as the internal control. The enrichment value at time zero was employed as the reference to calculate the fold changes.
ChIP assays
Soluble chromatin was prepared as described (Wei et al., 2006) and precipitated with anti-STAT1, anti-MUC1-C, anti-STAT5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a control non-immune IgG. The input chromatin lysate was 1% of that used for ChIP PCR (ChIP Protocol; Millipore, Billerica, MA, USA). For re-ChIP assays, complexes from the primary ChIP were eluted with 10 mM DTT, diluted in re-ChIP buffer and reimmunoprecipitated with anti-MUC1-C. For PCR, 2 ml for a 50 ml DNA extraction was used with 25-35 cycles of amplification.
Statistical analysis of breast cancer databases
Two publicly available databases were analyzed that contain breast tumor expressional data from 327 (Loi et al., 2007) and 155 (Chanrion et al., 2008) patients. All statistical analyses were performed using JMP 7.1 (SAS Institute Inc., Cary, NC, USA). The raw signal intensity for each probe set ID of interest for each patient was normalized to the average value of the probe set ID across the entire database and subsequently log 2 -transformed. Multiple probe set IDs for a given gene were averaged for each patient sample to obtain a representative expression value for each gene. Expression data were clustered using hierarchical clustering via Ward's method. To identify the genes that were differentially expressed between the two patient clusters, F-tests were used to test the null hypothesis of equal variance for each gene between the two patient clusters. Results of the F-test (equal or unequal variance) were entered into an unpaired two-tailed Student's t-test to test the null hypothesis of equal magnitude of gene expression of each gene between the two patient clusters. A gene expression score for the STAT1 pathway was determined for each patient sample by calculating the average log 2 level of expression across the 24-gene STAT1 pathway. STAT1 pathway expression (STAT1P þ ) was defined as having a gene expression score greater than zero. MUC1 expression (MUC1 þ ) was defined as having a log 2 normalized expression value greater than zero. Survival analyses were performed using proportional hazards and Kaplan-Meier statistics with log-rank tests to test the null hypothesis of no difference in survival functions between patient clusters.
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